{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:41:23Z","timestamp":1792003283305,"version":"4.4.0"},"reference-count":44,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020638","name":"Allergan Aesthetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>OnabotulinumtoxinA is licensed in many countries for simultaneous treatment of three areas of the upper face: glabellar lines, 20\u2009U; lateral canthal lines, 24\u2009U; and forehead lines, 20\u2009U.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To assess the onabotulinumtoxinA dosing science and dose\u2013response relationship in the treatment of upper facial lines (UFL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Key practical questions are addressed using available data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>OnabotulinumtoxinA doses were selected for Phase 3 registrational trials based on rigorous dose\u2010ranging studies. In clinical practice, it is important to consider the relationship between dose and efficacy outcomes, duration, and safety. Interstudy comparison of duration analyses is complicated by the lack of a single comprehensive definition, but trial data with standard onabotulinumtoxinA dosing in the glabella suggest a median effect duration of ~4\u2009months. Treatment of UFL at below the approved dose is associated with a shorter duration, inferior response rates, and lower patient satisfaction; there is no evidence that underdosing reduces adverse event risk. It may therefore be advisable to avoid going below the licensed dose unless there is a clear clinical rationale. By contrast, there is growing evidence that treatment outcomes can be further improved using doses above those currently licensed, without adversely affecting safety\u2014as demonstrated in the glabella. Further studies are needed to assess this in lateral canthal and forehead lines. Additional work is also required to examine potential ceiling doses and better understand the dose\u2013response relationship in patient subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Appropriate dosing of onabotulinumtoxinA is essential for maximizing benefit and ensuring patient satisfaction.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.70170","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T03:59:47Z","timestamp":1745639987000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Why Dosing Matters: A Closer Look at the Dose\u2013Response Relationship With <scp>OnabotulinumtoxinA<\/scp>"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9745-2369","authenticated-orcid":false,"given":"Wolfgang G.","family":"Philipp\u2010Dormston","sequence":"first","affiliation":[{"name":"Hautzentrum K\u00f6ln  Cologne Germany"},{"name":"Faculty of Health University Witten\/Herdecke  Witten Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Joseph","sequence":"additional","affiliation":[{"name":"Clinical Testing of Beverly Hills  Beverly Hills California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean D. A.","family":"Carruthers","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Fezza","sequence":"additional","affiliation":[{"name":"Center for Sight  Sarasota Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Kaya Skin Clinic  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Yasin","sequence":"additional","affiliation":[{"name":"Global Aesthetics Medical Affairs Allergan Aesthetics, an AbbVie Company  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Musumeci","sequence":"additional","affiliation":[{"name":"Global Aesthetics Medical Affairs Allergan Aesthetics, an AbbVie Company  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"e_1_2_14_2_1","unstructured":"American Society of Plastic Surgeons \u201cInaugural ASPS Insights and Trends Report: Cosmetic Surgery 2022 \u201d2024 www.plasticsurgery.org\/documents\/News\/Trends\/2022\/trends\u2010report\u2010cosmetic\u2010surgery\u20102022.pdf."},{"key":"e_1_2_14_3_1","unstructured":"International Society of Aesthetic Plastic Surgery \u201c2022 ISAPS International Survey on Aesthetic\/Cosmetic Procedures Performed in 2021 \u201d2024 www.isaps.org\/media\/vdpdanke\/isaps\u2010global\u2010survey_2021.pdf."},{"key":"e_1_2_14_4_1","unstructured":"Botox Cosmetic \u201cHighlights of Prescribing Information \u201d2024 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/103000s5303lbl.pdf."},{"key":"e_1_2_14_5_1","unstructured":"Vistabel \u201cSummary of Product Characteristics \u201d2024 www.medicines.ie\/medicines\/vistabel\u201034207\/spc."},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.121356"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.PRS.0000076504.79727.62"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000128"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000220"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000357"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001414"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001612"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001883"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15947"},{"issue":"1","key":"e_1_2_14_15_1","article-title":"Botulinum Neurotoxin Type A Exhibits a Linear Correlation Between Dose, Peak Efficacy, and Duration of Effect in Functional Assays","volume":"81","author":"Nicholson G. S.","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2013.05.004"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjac157"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14728"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01648.x"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.116.012658"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.3245"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afr084"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11071150"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.146324"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00015"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins16060266"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8030065"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12070440"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2005.31107"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-008-9199-6"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2005.31206"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2005.31070"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000626"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.01.005"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2012.02582.x"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.2165\/11530110-000000000-00000"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000002669"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13070494"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.11.1351"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/asjof\/ojab036"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.5.1382"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2023.07.021"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000340"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000275"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins15050342"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.70170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T06:37:32Z","timestamp":1758782252000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.70170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/jocd.70170"],"URL":"https:\/\/doi.org\/10.1111\/jocd.70170","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70170"}}